The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
Open accessAbstract
Significance Statement: Surrogate end points are needed to assess whether treatments are effective in the earlier stages of CKD. Measuring the effects of treatments on GFR decline, which leads to kidney failure, might be one way to identify early benefits of CKD treatments. So far regulators have not approved the use of GFR slope, the difference in the change in GFR between treatment groups over time, as an end point in CKD randomized, controlled trials because they are concerned that small treatment effects on GFR may not translate into meaningful clinical benefits. Using a Bayesian individual patient meta-analysis of 47 studies including 60,620 participants, the authors found, that for sufficiently large studies, treatment effects on GFR slope from baseline and from 3-month follow-up of 0.5–1.0 ml/min per 1.73 m 2/yr strongly predict benefits on clinical end points such as doubling of serum creatinine, GFR<15 ml/min per 1.73 m 2, or ESKD. GFR slope can play a useful role as a surrogate end point for CKD progression in clinical trials. Background: Surrogate end points are needed to assess whether treatments are effective in the early stages of CKD. GFR decline leads to kidney failure, but regulators have not approved using differences in the change in GFR from the beginning to the end of a randomized, controlled trial as an end point in CKD because it is not clear whether small changes in the GFR slope will translate to clinical benefits. Methods: To assess the use of GFR slope as a surrogate end point for CKD progression, we performed a meta-analysis of 47 RCTs that tested 12 interventions in 60,620 subjects. We estimated treatment effects on GFR slope (mean difference in GFR slope between the randomized groups), for the total slope starting at baseline, chronic slope starting at 3 months after randomization, and on the clinical end point (doubling of serum creatinine, GFR<15 ml/min per 1.73 m 2, or ESKD) for each study. We used Bayesian mixed-effects analyses to describe the association of treatment effects on GFR slope with the clinical end point and to test how well the GFR slope predicts a treatment’s effect on the clinical end point. Results: Across all studies, the treatment effect on 3-year total GFR slope (median R 2=0.97; 95% Bayesian credible interval [BCI], 0.78 to 1.00) and on the chronic slope (R 2 0.96; 95% BCI, 0.63 to 1.00) accurately predicted treatment effects on the clinical end point. With a sufficient sample size, a treatment effect of 0.75 ml/min per 1.73 m 2/yr or greater on total slope over 3 years or chronic slope predicts a clinical benefit on CKD progress with at least 96% probability. Conclusions: With large enough sample sizes, GFR slope may be a viable surrogate for clinical end points in CKD RCTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Self-citationConducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Feature Selection with the Boruta Package
Kursa, M. B., & Rudnicki, W. R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i11 · Cited by 5,659
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Self-citationLevey, A. S., & Coresh, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60178-5 · Cited by 1,841
Self-citationTolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Self-citation
Cited by
Levey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.009 · Cited by 591
Self-citationEffects of Allopurinol on the Progression of Chronic Kidney Disease
Badve, S. V., Pascoe, E. M., Tiku, A., Boudville, N., Brown, F. G., Cass, A., Clarke, P., Dalbeth, N., Day, R. O., de Zoysa, J. R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915833 · Cited by 473
Self-citationRenin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease
Bhandari, S., Mehta, S., Khwaja, A., Cleland, J. G. F., Ives, N., Brettell, E., Chadburn, M., & Cockwell, P. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210639 · Cited by 328
Measured and estimated glomerular filtration rate: current status and future directions
Levey, A. S., Coresh, J., Tighiouart, H., Greene, T., & Inker, L. A. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0191-y · Cited by 312
Self-citationHeerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306
Self-citation
Metadata
- Authors
- Inker, L. A., Heerspink, H. J. L., Tighiouart, H., Levey, A. S., Coresh, J., Gansevoort, R. T., Simon, A. L., Ying, J., Beck, G. J., Wanner, C., Floege, J., Li, P. K.-T., Perkovic, V., Vonesh, E. F., & Greene, T.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2019-07-10
- Volume
- 30
- Issue
- 9
- Pages
- 1735-1745
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2962169757
- Cited by
- 310
- References
- 40
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1681/asn.2019010007
- The paper
- Inker, L. A., Heerspink, H. J. L., Tighiouart, H., Levey, A. S., Coresh, J., Gansevoort, R. T., Simon, A. L., Ying, J., Beck, G. J., Wanner, C., Floege, J., Li, P. K.-T., Perkovic, V., Vonesh, E. F., & Greene, T. (2019). GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2019010007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.